Biaxin Could Benefit From Flu Vaccine Shortage Ahead Of Generic Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott cautions that it is too early in the flu season to accurately predict the potential sales impact on the antibiotic brand, which is expected to face generic competition in May 2005. The company’s fourth quarter forecast assumes a conservative impact from the flu vaccine shortage.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Biaxin Transition: XL Accounts For 65% Of Franchise Sales
Biaxin XL (extended-release clarithromycin) accounts for approximately 65% of sales of the Biaxin franchise, Abbott said Jan. 18
Biaxin Transition: XL Accounts For 65% Of Franchise Sales
Biaxin XL (extended-release clarithromycin) accounts for approximately 65% of sales of the Biaxin franchise, Abbott said Jan. 18